These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27069189)

  • 41. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
    Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
    Özdemir E; Çiçek T; Kaya MO
    Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
    Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
    Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
    Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
    Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate tumour markers and differentiation grade in prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Alfthan OS
    Br J Urol; 1990 Dec; 66(6):635-8. PubMed ID: 1702339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vitamin D deficiency promotes prostate cancer growth in bone.
    Zheng Y; Zhou H; Ooi LL; Snir AD; Dunstan CR; Seibel MJ
    Prostate; 2011 Jun; 71(9):1012-21. PubMed ID: 21541977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
    Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
    Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases.
    Papatheofanis FJ
    Br J Radiol; 1997 Jun; 70(834):594-8. PubMed ID: 9227252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M; Jonas D; Oremek GM
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical markers of bone metabolism in breast cancer.
    Lyubimova NV; Kozharskaya GV; Portnoi SM; Kushlinskii NE
    Bull Exp Biol Med; 2014 Oct; 157(6):769-72. PubMed ID: 25342482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.
    Sasaki H; Yu CY; Dai M; Tam C; Loda M; Auclair D; Chen LB; Elias A
    Breast Cancer Res Treat; 2003 Feb; 77(3):245-52. PubMed ID: 12602924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TRACP 5b and CTX as osteological markers of delayed fracture healing.
    Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
    Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.